CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Symphogen A/S is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Symphogen A/S
Pederstrupvej 93
BALLERUP, 2750  Denmark

This is a Subsidiary, click here for the Parent Company

Business Summary
Symphogen A/S is a Denmark-based biopharmaceutical Company which is focused on applying antibody platform and capabilities in the discovery and early development of differentiated antibody therapeutics, either as combination or stand-alone therapies supporting Servier's R&D strategy. The Company is working on several clinical development projects including Sym015 and Sym004.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201812/31/2018Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board ClaudeBertrand
Chief Executive Officer, Director ChristopheThurieau
Senior Vice President of People and Facility LisbetLoschenkohl 55
Senior Vice President, CMC Rikke B.Jensen
Senior Vice President, Head of Biologic Drug Design HanneRomedahl 51

General Information
Number of Employees: 125 (As of 12/31/2018)
Outstanding Shares: 15,403,759 (As of 12/31/2018)


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023